Investigating the Effect of Synbiotics on Inflammatory Indicators
Phase 3
- Conditions
- Sepsis.Sepsis, unspecified organismA41.9
- Registration Number
- IRCT20230523058266N1
- Lead Sponsor
- Vice President of Research and Technology, Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Any Patient admitted to the Pediatric Intensive Care Unit with a Diagnosis of Sepsis and Possibility of Hospitalization for more than 4 Days in the PICU
children aged 1 month to 10 years
consent of parent to participation of their children to study
Exclusion Criteria
Immunodeficiency or Malignancy
steroid Therapy or Immunotherapy
Congenital Abnormalities Incompatible with life
Previous Gastrointestinal Surgery in the last month
Ulcerative Colitis
Short Bowel Syndrome
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Interleukin-6. Timepoint: The beginning of the study (before the start of the intervention) and the 7th day after the start of taking the synbiotic supplement. Method of measurement: Interleukin 6 ELISA kit.
- Secondary Outcome Measures
Name Time Method C reactive protien. Timepoint: The beginning of the study (before the start of the intervention), 7 days after the start of taking the synbiotic supplement. Method of measurement: Measurement of serum levels.;Tumor necrosis factor. Timepoint: The beginning of the study (before the start of the intervention), 7 days after the start of taking the synbiotic supplement. Method of measurement: Measurement of serum levels.;Erythrocyte sedimentation rate. Timepoint: The beginning of the study (before the start of the intervention), 7 days after the start of taking the synbiotic supplement. Method of measurement: Measurement of serum levels.